<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717064</url>
  </required_header>
  <id_info>
    <org_study_id>YP40218</org_study_id>
    <nct_id>NCT03717064</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers</brief_title>
  <official_title>An Open-Label, Fixed Sequence, Two-Period Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to characterize the interaction between RO7049389 and the
      cholesterol-lowering drug, pitavastatin, in healthy volunteers. There is no intended clinical
      benefit to this study. The total duration of the study for each participant is approximately
      12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Actual">December 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Period 1: Maximum Plasma Concentration (Cmax) of Pitavastatin</measure>
    <time_frame>Period 1 Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 1: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin</measure>
    <time_frame>Period 1 Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 1: Time to Maximum Concentration (Tmax) of Pitavastatin</measure>
    <time_frame>Period 1 Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 1: Apparent Total Clearance (CL/F) of Pitavastatin</measure>
    <time_frame>Period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 1: Volume of Distribution (V/F) of Pitavastatin</measure>
    <time_frame>Period 1 Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 1: Elimination Half-Life (T1/2) of Pitavastatin</measure>
    <time_frame>Period 1 Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Maximum Plasma Concentration (Cmax) of Pitavastatin</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Time to Maximum Concentration (Tmax) of Pitavastatin</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Apparent Total Clearance (CL/F) of Pitavastatin</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Volume of Distribution (V/F) of Pitavastatin</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Elimination Half-Life (T1/2) of Pitavastatin</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>From the start of Period 1 through safety follow-up (Period 2, Day 34)</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Cmax of RO7049389</measure>
    <time_frame>Period 2 Days 3-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUC-tau of RO7049389</measure>
    <time_frame>Period 2 Days 3-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Cmax of Pitavastatin Lactone</measure>
    <time_frame>Period 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: AUC0-inf of Pitavastatin Lactone</measure>
    <time_frame>Period 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: AUC Ratio of Pitavastatin Lactone to Pitavastatin</measure>
    <time_frame>Period 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Cmax of Pitavastatin Lactone</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUC0-inf of Pitavastatin Lactone</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: AUC Ratio of Pitavastatin Lactone to Pitavastatin</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Pitavastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 and up to 21 days.
Period 2: Participants will receive RO7049389 on Days 1-6. Participants will also receive a single dose of pitavastatin on Day 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7049389</intervention_name>
    <description>RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.</description>
    <arm_group_label>Pitavastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.</description>
    <arm_group_label>Pitavastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy, as judged by the Investigator. Healthy status is defined by absence of
             evidence of any active or chronic disease following a detailed medical and surgical
             history, a complete physical examination including vital signs, 12-lead ECG, and based
             on the laboratory safety test results at screening and Day -1

          -  Body mass index (BMI) between 18 to 30 kg/m2 (inclusive) at screening

          -  Female participants: 1) Must be either surgically sterile (by means of hysterectomy
             and/or bilateral oophorectomy and/or bilateral salpingectomy) or post-menopausal for
             at least one year (defined as amenorrhea &gt;/=12 consecutive months without another
             cause, and confirmed by follicle-stimulating hormone (FSH) level. 2) Participants must
             not be pregnant or lactating.

          -  Male participants: 1) Female partners must not be pregnant or lactating. 2) Must agree
             to remain abstinent (refrain from heterosexual intercourse) or must agree to use a
             condom with spermicide during the treatment period and for at least 28 days after the
             last dose of study drug with female partners of childbearing potential. 3) Must agree
             to refrain from donating sperm during the treatment period and for at least 28 days
             after the last dose of study drug

        Exclusion Criteria

          -  Have a history or symptoms of any clinically significant cardiovascular, respiratory,
             hepatic, renal, gastrointestinal, endocrine, hematological, oncologic or neurological
             disorders capable of significantly altering the absorption, metabolism, or elimination
             of drugs; of constituting a risk when taking the study treatment; or of interfering
             with the interpretation of data

          -  Confirmed (based on the average of 3 separate resting BP measurements in a supine
             position, after at least 5 minutes rest) systolic BP greater than 140 or less than 90
             mmHg, and diastolic BP greater than 90 or less than 50 mmHg at screening and Day -1

          -  Personal history or family history of congenital long QT syndrome and/or cardiac
             sudden death

          -  History of Gilbert's syndrome

          -  Participants who have had significant acute infection, e.g., influenza, local
             infection, acute gastrointestinal symptoms or any other clinically significant illness
             within two weeks of dose administration

          -  Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any
             drug, or multiple drug allergies (non-active hay fever is acceptable)

          -  Taking any herbal medications or substances (e.g., tea) or supplements (including
             vitamins), or traditional Chinese medicines (TCM) or over-the-counter (OTC)
             medications within 14 days of first dosing or within 5 times the elimination half-life
             of the medication prior to first dosing, whichever is longer

          -  History of having received any systemic anti-neoplastic (including radiation) or
             immunemodulatory treatment (including systemic oral or inhaled corticosteroids) &lt;/=6
             months prior to the first dose of study drug or the expectation that such treatment
             will be needed at any time during the study

          -  Are currently enrolled in or have participated in any other clinical study involving
             an investigational product or in any other type of medical research within the last 30
             days or 5 half lives (whichever is longer)

          -  Donation or loss of blood or blood products in excess of 500 mL within 3 months of
             screening and for the duration of the study

          -  Positive test for drugs of abuse (including recreational drugs) and/or positive
             alcohol test and/or positive cotinine test at screening and on Day -1

          -  Positive test at screening of any of the following: Hepatitis A virus (HAV IgM Ab),
             hepatitis B virus (HBsAg or HBcAb), hepatitis C virus (HCV RNA or HCV Ab) or human
             immunodeficiency virus (HIV-1 and HIV-2 Ab)

          -  History of alcohol consumption exceeding 2 standard drinks per day on average (1
             standard drink = 10 grams of alcohol) and/or drug abuse within 12 months of screening

          -  Use of &gt;5 cigarettes or equivalent nicotine-containing product per day prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-LaRoche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Research Unit - Daytona</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <results_first_submitted>November 25, 2019</results_first_submitted>
  <results_first_submitted_qc>December 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 10, 2020</results_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03717064/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study recruited healthy adult participants at one site in the United States.</recruitment_details>
      <pre_assignment_details>This study had two periods. Period 1: Participants received a single dose of pitavastatin, followed by a washout period of 7-21 days. Period 2: Participants received a single dose of pitavastatin along with a twice-daily dose of RO7049389.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pitavastatin/RO7049389</title>
          <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pitavastatin/RO7049389</title>
          <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Period 1: Maximum Plasma Concentration (Cmax) of Pitavastatin</title>
        <time_frame>Period 1 Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Maximum Plasma Concentration (Cmax) of Pitavastatin</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 1: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin</title>
        <time_frame>Period 1 Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 1: Time to Maximum Concentration (Tmax) of Pitavastatin</title>
        <time_frame>Period 1 Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Time to Maximum Concentration (Tmax) of Pitavastatin</title>
          <units>hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.5" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 1: Apparent Total Clearance (CL/F) of Pitavastatin</title>
        <time_frame>Period 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Apparent Total Clearance (CL/F) of Pitavastatin</title>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 1: Volume of Distribution (V/F) of Pitavastatin</title>
        <time_frame>Period 1 Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Volume of Distribution (V/F) of Pitavastatin</title>
          <units>Liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 1: Elimination Half-Life (T1/2) of Pitavastatin</title>
        <time_frame>Period 1 Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Elimination Half-Life (T1/2) of Pitavastatin</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Maximum Plasma Concentration (Cmax) of Pitavastatin</title>
        <time_frame>Period 2 Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Maximum Plasma Concentration (Cmax) of Pitavastatin</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin</title>
        <time_frame>Period 2 Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" spread="50.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Time to Maximum Concentration (Tmax) of Pitavastatin</title>
        <time_frame>Period 2 Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Time to Maximum Concentration (Tmax) of Pitavastatin</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.5" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Apparent Total Clearance (CL/F) of Pitavastatin</title>
        <time_frame>Period 2 Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Apparent Total Clearance (CL/F) of Pitavastatin</title>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Volume of Distribution (V/F) of Pitavastatin</title>
        <time_frame>Period 2 Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Volume of Distribution (V/F) of Pitavastatin</title>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220" spread="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Elimination Half-Life (T1/2) of Pitavastatin</title>
        <time_frame>Period 2 Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Elimination Half-Life (T1/2) of Pitavastatin</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.78" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>From the start of Period 1 through safety follow-up (Period 2, Day 34)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Cmax of RO7049389</title>
        <time_frame>Period 2 Days 3-4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Cmax of RO7049389</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RO7049389</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15400" spread="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RO7049389 + Pitavastatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17600" spread="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUC-tau of RO7049389</title>
        <time_frame>Period 2 Days 3-4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUC-tau of RO7049389</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RO7049389</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62700" spread="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RO7049389 + Pitavastatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68500" spread="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Cmax of Pitavastatin Lactone</title>
        <time_frame>Period 1 Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Cmax of Pitavastatin Lactone</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: AUC0-inf of Pitavastatin Lactone</title>
        <time_frame>Period 1 Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: AUC0-inf of Pitavastatin Lactone</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: AUC Ratio of Pitavastatin Lactone to Pitavastatin</title>
        <time_frame>Period 1 Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: AUC Ratio of Pitavastatin Lactone to Pitavastatin</title>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" lower_limit="2.17" upper_limit="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Cmax of Pitavastatin Lactone</title>
        <time_frame>Period 2 Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Cmax of Pitavastatin Lactone</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUC0-inf of Pitavastatin Lactone</title>
        <time_frame>Period 2 Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUC0-inf of Pitavastatin Lactone</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: AUC Ratio of Pitavastatin Lactone to Pitavastatin</title>
        <time_frame>Period 2 Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin/RO7049389</title>
            <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: AUC Ratio of Pitavastatin Lactone to Pitavastatin</title>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.636" lower_limit="0.504" upper_limit="0.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of Period 1 through safety follow-up (Period 2, Day 34)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pitavastatin/RO7049389</title>
          <description>Period 1: Participants received a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 days and up to 21 days.
Period 2: Participants received RO7049389 on Days 1-6. Participants also received a single dose of pitavastatin on Day 4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>1-800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

